Akari Therapeutics, Plc AKTX
7.13 USD -0.53 (-6.92%)
At closeNov 10, 2026, 4:00 PM EST
7.13 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
6.94 Day range 7.58
3.02 52-week range 29.32
- YTD
- -38.32%
- 1 year
- -71.62%
News
globenewswire.com Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
benzinga.com Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
globenewswire.com Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
globenewswire.com Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value
benzinga.com Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of…
globenewswire.com Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
defenseworld.net Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
defenseworld.net Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell? Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $9.65 and traded as…
globenewswire.com Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September
globenewswire.com Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference Video webcast now available here- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.- benzinga.com Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced new preclinical data…
globenewswire.com Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
benzinga.com Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome…
globenewswire.com Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
globenewswire.com Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating…
defenseworld.net Akari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average – Here’s What Happened Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.24 and traded as…
benzinga.com Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.
globenewswire.com Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research…
globenewswire.com Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing…
benzinga.com Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
globenewswire.com Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA…
globenewswire.com Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
globenewswire.com Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026 Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
globenewswire.com Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28,…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
feeds.benzinga.com Why Akari Therapeutics Stock Is Falling On Tuesday? Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
benzinga.com Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Crude Oil Edges Higher; US Consumer Sentiment Falls In May US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
benzinga.com Akari Therapeutics Stock Jumps On Promising Preclinical Data Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated…
benzinga.com Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ's Wholesale Club stock falls 7% after earnings.
benzinga.com Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session